| USE OF INTERFERON IN THE CONTROL OF CANINE ATOPIC DERMATITIS: A NEW OPPORTUNITY Results of a clinical double-blind, controlled (versus a Reference product) trial were communicated to the World Congress of Veterinary Dermatology (WCVD) in Hong Kong, last November 2008. For more info on the study, please consult the abstract (carlotti et al., 2008), protcocol and data sheet on the web site.
| | Welcome to Vetinterferon | | | | This is an information platform on interferons and their use in small animal medicine.
The aim of this site is to enhance the knowledge on interferons by providing scientific references, field reports and general information. | |
« Scientific references » are articles or congress abstracts published on interferons related to veterinary medicine. They cover different aspects that can be useful to the veterinary profession.
« Field reports » contain clinical cases published by vets who experienced the use of interferons in different areas. They are briefly reported to provide helpful information in practice.
All these data are regularly updated.
| | | |
| | | | | | | | |
| |
| Recent updates | | rFeIFN-omega: use in feline fibrosaroma: 13 cases | | This review of 13 personal cases shows that interferon omega may play an interesting role in the management of feline fibrosarcoma. It is therefore part of the very promising immunotherapeutic approach to cancer treatment. | |
more... | | | Interferon as adjuvant treatment in fibrosarcoma | | Personal experience of Dr Sochat on the use of feline interferon in fibrosarcoma. | |
more... | | | Fibrosarcomas: a pilot study with IFN-omega | | This pilot study (20 cats), published in the Journal of Veterinary Internal Medicine, shows promising results in the management of feline fibrosarcoma. This could be a very interesting step forward in the management of these aggressive tumours in the Cat. | |
more... | | | Adjuvant immunotherapy of fibrosarcoma with rFeIFN | | This open-labelled prospective clinical trial shows that rFeIFN-omega, safe and well tolerated, is able to induce MHC-I expression in feline fibrosarcoma cell lines, which renders the tumour cells susceptible to be attacked by the immune system. | |
more... | |
|